This bill amends the Public Health Code by adding Section 17757c, which establishes new regulations for manufacturers, wholesalers, and wholesale distributor-brokers regarding the acquisition and delivery of 340B drugs. Specifically, it prohibits these entities from denying, restricting, or discriminating against 340B entities or authorized pharmacies in their ability to acquire or receive 340B drugs. However, exceptions are made if such actions are authorized by state or federal law.

Additionally, starting July 1, 2026, the bill mandates that 340B entities and manufacturers submit annual reports to the Department of Health and Human Services, as well as to the House and Senate fiscal agencies. These reports must include detailed information about the 340B program, compliance with audits, and any significant price increases for prescription drugs. The Department is also required to make these reports publicly accessible on its website. The bill aims to enhance transparency and accountability in the 340B drug pricing program.

Statutes affected:
Senate Introduced Bill: 333.1101, 333.25211
As Passed by the Senate: 333.1101, 333.25211